His primary areas of study are Leishmaniasis, Visceral leishmaniasis, Leishmania donovani, Genetics and Immunology. His Leishmaniasis research is multidisciplinary, relying on both Internal medicine, Drug resistance and Leishmania. In the subject of general Leishmania, his work in Amastigote is often linked to Cost effectiveness, thereby combining diverse domains of study.
His Visceral leishmaniasis research is multidisciplinary, incorporating elements of Vector, Incidence, Surgery, Virology and Veterinary medicine. His study in Leishmania donovani is interdisciplinary in nature, drawing from both Transmission, Mortality rate, Gene expression and Typing. The Protozoal disease research he does as part of his general Immunology study is frequently linked to other disciplines of science, such as Acquired immunodeficiency syndrome, therefore creating a link between diverse domains of science.
His primary scientific interests are in Leishmaniasis, Leishmania donovani, Leishmania, Genetics and Visceral leishmaniasis. Jean-Claude Dujardin usually deals with Leishmaniasis and limits it to topics linked to Virology and Parasitology. His Leishmania donovani research includes themes of Miltefosine, Amastigote, Drug resistance, Microbiology and Sodium stibogluconate.
His work deals with themes such as Antimonial, Drug development, Drug and Metabolomics, which intersect with Drug resistance. The Leishmania study combines topics in areas such as Kinetoplastida, Aneuploidy, Molecular biology, DNA sequencing and Polymerase chain reaction. His Visceral leishmaniasis study incorporates themes from Veterinary medicine, Epidemiology and Whole genome sequencing.
Jean-Claude Dujardin focuses on Genetics, Leishmania, Leishmania donovani, Visceral leishmaniasis and Drug resistance. As a part of the same scientific family, he mostly works in the field of Leishmania, focusing on DNA sequencing and, on occasion, Ploidy. The various areas that Jean-Claude Dujardin examines in his Leishmania donovani study include Amastigote and Haplotype.
His Visceral leishmaniasis study necessitates a more in-depth grasp of Leishmaniasis. His Leishmaniasis study improves the overall literature in Immunology. His Drug resistance research incorporates elements of Miltefosine and Drug discovery.
His primary scientific interests are in Leishmania donovani, Genetics, Visceral leishmaniasis, Leishmaniasis and Gene. His Leishmania donovani study combines topics in areas such as Mutation rate and Haplotype. His work in Genetics covers topics such as Leishmania which are related to areas like Clinical trial.
His biological study spans a wide range of topics, including Metabolome, Virulence, Genotype and Genomics. His Leishmaniasis research is multidisciplinary, incorporating perspectives in Drug resistance and Virology. His studies in Drug resistance integrate themes in fields like Drug development, Computational biology, Immunology and Drug discovery.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Cutaneous leishmaniasis – Authors' reply
Richard Reithinger;Richard Reithinger;Jean-Claude Dujardin;Hechmi Louzir;Claude Pirmez.
Lancet Infectious Diseases (2008)
Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy
Julius Lukeš;Isabel L. Mauricio;Gabriele Schönian;Jean Claude Dujardin.
Proceedings of the National Academy of Sciences of the United States of America (2007)
Molecular diagnosis of leishmaniasis: current status and future applications.
Richard Reithinger;Richard Reithinger;Richard Reithinger;Jean-Claude Dujardin.
Journal of Clinical Microbiology (2007)
Spread of Vector-borne Diseases and Neglect of Leishmaniasis, Europe
Jean-Claude Dujardin;Lenea Campino;Carmen Cañavate;Jean-Pierre Dedet.
Emerging Infectious Diseases (2008)
Chromosome and gene copy number variation allow major structural change between species and strains of Leishmania
Matthew B. Rogers;James D. Hilley;Nicholas J. Dickens;Jon Wilkes.
Genome Research (2011)
Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance
Tim Downing;Hideo Imamura;Saskia Decuypere;Taane G Clark.
Genome Research (2011)
Drug resistance and treatment failure in leishmaniasis: A 21st century challenge
Alicia Ponte-Sucre;Francisco Gamarro;Jean-Claude Dujardin;Michael P. Barrett.
PLOS Neglected Tropical Diseases (2017)
Increasing Failure of Miltefosine in the Treatment of Kala-azar in Nepal and the Potential Role of Parasite Drug Resistance, Reinfection, or Noncompliance
Suman Rijal;Bart Ostyn;Surendra Uranw;Surendra Uranw;Keshav Rai.
Clinical Infectious Diseases (2013)
Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis.
Jorge Arevalo;Jorge Arevalo;Luis Ramirez;Vanessa Adaui;Mirko Zimic.
The Journal of Infectious Diseases (2007)
Efficacy of Miltefosine in the Treatment of Visceral Leishmaniasis in India After a Decade of Use
Shyam Sundar;Anup Singh;Madhukar Rai;Vijay K Prajapati.
Clinical Infectious Diseases (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: